 Avalon GloboCare Corp NASDAQ:AVCO told shareholders that its acquisition of Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing, clinical development programs, and pre-clinical research, will enhance the companys capabilities in cell and gene therapy. The deal, which was announced June 13, 2021, will see Avalon enter into a share purchase agreement for an aggregate of 81 million shares of its common stock, valued at US0.0001 per share. 